ImmunoGen, Inc.·4

Feb 8, 5:31 PM ET

Berkenblit Anna 4

4 · ImmunoGen, Inc. · Filed Feb 8, 2022

Insider Transaction Report

Form 4
Period: 2022-02-04
Berkenblit Anna
VP & Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-02-04$5.32/sh+311,700$1,658,244311,700 total
    Exercise: $5.32From: 2023-02-04Exp: 2032-02-04Common Stock (311,700 underlying)
Footnotes (1)
  • [F1]These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.

Documents

1 file
  • 4
    edgar.xmlPrimary

    FORM 4 -